国: マルタ
言語: 英語
ソース: Medicines Authority
CAPTOPRIL
Adelco-Chromatourgia Anthinon E. Colocotronis Bros S.A. 37 Pireos Str, 183 46, Moschato, Athens, Greece
C09AA01
CAPTOPRIL 50 mg
TABLET
CAPTOPRIL 50 mg
POM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
Withdrawn
2005-10-04
ΝΟ R ΜΟ LOSE 50MG (Captopril) PATIENT INFORMATION LEAFLET 1.1 NAME OF THE MEDICINAL PRODUCT ΝΟ R ΜΟ LOSE 50MG 1.2 COMPOSITION _ACTIVE INGREDIENT:_ Captopril _EXCIPIENTS: _ Tablets 50 mg: Lactose Monohydrate, Starch Maize, Magnesium Stearate, Cellulose Microcrystalline. 1.3 PHARMACEUTICAL FORM Tablets 50 mg: White, flat tablets on one side scored and with the inscription ‘‘ADELCO’’ on the other. 1.4 ACTIVE INGREDIENT CONTENT Each Normolose tablet 50 mg contains 50 mg Captopril. 1.5 DESCRIPTION-PACKAGING - ΒΤ x 20 tablets (2 PVC/ALU blisters x 10 tabs) - BT x 1000 tablets (100 PVC/ALU blisters x 10 tabs) (Not all pack sizes may be marketed) 1.6 PHARMACOTHERAPEUTIC CATEGORY ACE Inhibitors 1.7 MARKETING AUTHORIZATION HOLDER-MANUFACTURER: ADELCO CHROMATOURGIA ATHINON E. COLOCOTRONIS BROS. S.A. 37, PIREOS STR., 183 46 MOSCHATO,ATHENS-GREECE TEL: +30 210 4819 311-4 FAX: +30 210 4816 790 2. WHAT YOU SHOULD KNOW ABOUT THE DRUG PRESCRIBED BY YOUR PHYSICIAN 2.1 GENERAL INFORMATION Captopril is a particularly selective, competitive inhibitor of angiotensin-I - converting enzyme (ACE inhibitors). In patients with hypertension, captopril causes a reduction in the arterial pressure both in a supine and upright body position, without leading to any compensatory increase of cardiac frequency, nor to any water or sodium retention. In most patients, the antihypertensive action commences approximately 15 to 30 min after the oral administration of captopril. The maximum activity was accomplished after 60 to 90 minutes. The maximum reduction in the arterial pressure of a pre-deter 完全なドキュメントを読む
Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE PHARMACEUTICAL PRODUCT NORMOLOSE tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION NORMOLOSE 50 mg Captopril / Tablet NORMOLOSE 100 mg Captopril / Tablet For excipients, (see Section 6.1 List of excipients) 3. PHARMACEUTICAL FORM Tablet NORMOLOSE 50 mg Captopril / Tablet: White, flat tablets 8 mm in diameter NORMOLOSE 100 mg Captopril / Tablet, White, flat tablets 10 mm in diameter 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS HYPERTENSION : NORMOLOSE is indicated for the treatment of hypertension. CARDIAC FAILURE : NORMOLOSE, is indicated for the treatment of chronic heart failure, with reduced ventricular systolic function, in combination with diuretics, and in combination with digitalis and beta-blockers, when it is indicated. MYOCARDIAL INFARCTION: - Short term (4 weeks duration): NORMOLOSE is indicated for the treatment of patients whose clinical condition has been stable within the first 24 hours after myocardial infarction. - Long term prophylaxis of symptomatic heart failure : NORMOLOSE is indicated for patients with asymptomatic left ventricular dysfunction (ejection fraction ≤ 40%) when in stable clinical condition. Type I diabetic nephropathy : NORMOLOSE is indicated for the treatment of Type I diabetic patients with macroglobulinaemic diabetic nephropathy (see Section 5.1 Pharmacodynamics) 4.2. POSOLOGY AND MODE OF ADMINISTRATION The dose should be individualized according to patient clinical picture (see Section 4.4 Special warnings and special precautions on use) and blood pressure response. The recommended maximum daily dose is 150 mg. NORMOLOSE may be administered before, during or after meals. HYPERTENSION : The recommended initiation dose is 25-50 mg daily, administered 完全なドキュメントを読む